Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online April 1, 2023.
Article Versions
- Latest version (March 1, 2023 - 04:00).
- You are currently viewing a Latest version of this article (April 1, 2023 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2023 The Journal of Rheumatology
Author Information
- Sofia Exarchou,
- Johan K. Wallman,
- Daniela Di Giuseppe,
- Eva Klingberg,
- Valgerdur Sigurdardottir,
- Sara Wedrén,
- Ulf Lindström,
- Carl Turesson,
- Lennart T.H. Jacobsson and
- Johan Askling
- S. Exarchou, MD, PhD, Department of Clinical Sciences Malmö, Rheumatology, Lund University, Malmö.
- J.K. Wallman, MD, PhD, Department of Clinical Sciences Lund, Rheumatology, Lund University, and Department of Rheumatology, Skåne University Hospital, Lund.
- D. Di Giuseppe, PhD, J. Askling, MD, PhD, Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm
- E. Klingberg, MD, PhD, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, and Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg.
- V. Sigurdardottir, MD, Center for Clinical Research (CKF) Dalarna, Uppsala University, and Department of Rheumatology, Falun Hospital, Falun.
- S. Wedrén, MD, PhD, Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, and Department of Rheumatology, Karolinska University Hospital, Stockholm.
- U. Lindström, MD, PhD, L.T.H. Jacobsson, MD, PhD, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg.
- C. Turesson, MD, PhD, Department of Clinical Sciences Malmö, Rheumatology, Lund University, and Department of Rheumatology, Skåne University Hospital, Malmö, Sweden.
- U. Lindström, MD, PhD, L.T.H. Jacobsson, MD, PhD, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg.
- D. Di Giuseppe, PhD, J. Askling, MD, PhD, Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm.
-
This study was supported by AbbVie (4-1624/2020), Amgen (4-2584/2019), Eli Lilly (4-691/2020), Novartis (4-2568/2019), and Pfizer (4-3321/2019). The sponsors were allowed to comment on the study protocol and were provided with a report of the results, but had no influence on the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the manuscript. This study was further supported by unrestricted grants from the Swedish Rheumatism Association (R-837511), the Swedish Psoriasis Foundation (decision date: August 23, 2019), the Gösta A Karlsson 60-year Foundation (decision date: August 24, 2019), and Skåne University Hospital (decision date: June 27, 2018).
SE reports consulting for AbbVie, Amgen, Janssen-Cilag, Novartis, and UCB Pharma. JKW reports consulting for AbbVie, Amgen, Celgene, Eli Lilly, and Novartis. EK reports grant/research support from Roche, consulting for Novartis, and being on the speakers bureau for Eli Lilly. VS reports consulting for Novartis, Sanofi, and AstraZeneca. CT reports grant/research support from BMS, consulting for Roche, and being on the speakers bureau for AbbVie, BMS, Nordic Drugs, Pfizer, and Roche. LTHJ reports consulting for AbbVie, Eli Lilly, Janssen, Novartis, and Pfizer. JA reports grant/research support from the following entities, and acts or has acted as principal investigator for agreements between the Karolinska Institutet and the following entities, mainly in the context of the Anti-Rheumatic Therapies in Sweden national safety monitoring programme of immunomodulators in rheumatology: AbbVie, BMS, Eli Lilly, Merck, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB Pharma. The remaining authors declare no conflicts of interest relevant to this article.
Accepted for publication February 14, 2023.
- Address correspondence to Dr. S. Exarchou, Department of Clinical Sciences Malmö, Rheumatology, Lund University, Jan Waldenströms gata 1B, 205 02, Malmö, Sweden. Email: sofiaexar@hotmail.com.